Quick Answer
Propanc Biopharma, Inc. reported Cash and Equivalents of $4.1 thousand for fiscal year 2022.
Propanc Biopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $4.1K | +80.4% |
| 2021 | $2.3K | -96.6% |
| 2020 | $67.0K | -23.7% |
| 2014 | $87.8K | — |
| 2013 | $0.00 | -100.0% |
| 2012 | $179.00 | +35.6% |
| 2011 | $132.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $93.2K | -30.4% | +280.9% |
| December 31, 2022 | $24.5K | -66.8% | +26.2% |
| September 30, 2022 | $19.4K | -57.7% | +376.9% |
| June 30, 2022 | $4.1K | +80.4% | -97.0% |
| March 31, 2022 | $133.9K | +827.2% | +81.9% |
| December 31, 2021 | $73.6K | — | +60.7% |
| September 30, 2021 | $45.8K | — | +1931.8% |
| June 30, 2021 | $2.3K | -96.6% | -84.4% |
- Propanc Biopharma, Inc. showed an increase of +80.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2022 period, Propanc Biopharma, Inc.’s cash and equivalents has grown by 2981.1% (from $132.00 to $4.1 thousand).
- The most recent figure is from Propanc Biopharma, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on September 28, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: